SARS-CoV-2-associated gut microbiome alteration; A new contributor to colorectal cancer pathogenesis

The emergence of a novel coronavirus, COVID-19, in December 2019 led to a global pandemic with more than 170 million confirmed infections and more than 6 million deaths (by July 2022). Studies have shown that infection with SARS-CoV-2 in cancer patients has a higher mortality rate than in people wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mozaffari, Shahrooz Amin, Salehi, Ali, Mousavi, Elnaz, Zaman, Burhan Abdullah, Nassaj, Ali Eslambol, Ebrahimzadeh, Farnoosh, Nasiri, Hadi, Valedkarimi, Zahra, Adili, Ali, Asemani, Ghazaleh, Akbari, Morteza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier GmbH. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477615/
https://www.ncbi.nlm.nih.gov/pubmed/36191449
http://dx.doi.org/10.1016/j.prp.2022.154131
Descripción
Sumario:The emergence of a novel coronavirus, COVID-19, in December 2019 led to a global pandemic with more than 170 million confirmed infections and more than 6 million deaths (by July 2022). Studies have shown that infection with SARS-CoV-2 in cancer patients has a higher mortality rate than in people without cancer. Here, we have reviewed the evidence showing that gut microbiota plays an important role in health and is linked to colorectal cancer development. Studies have shown that SARS-CoV-2 infection leads to a change in gut microbiota, which modify intestinal inflammation and barrier permeability and affects tumor-suppressor or oncogene genes, proposing SARS-CoV-2 as a potential contributor to CRC pathogenesis

Ejemplares similares